Yue Yongjian, Sun Qing, Xiao Lu, Liu Shengguo, Huang Qijun, Wang Minlian, Huo Mei, Yang Mo, Fu Yingyun
Key Laboratory of Shenzhen Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Disease, The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, China.
Shenzhen Key Laboratory of Reproductive Immunology for Peri-implantation, Fertility Center, Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
Front Genet. 2019 Sep 13;10:844. doi: 10.3389/fgene.2019.00844. eCollection 2019.
Genetic variants in the gene have been shown to be associated with antithrombin deficiency, which subsequently contributes to the susceptibility to venous thrombosis. However, several other studies have shown conflicting results regarding the association of gene polymorphisms (rs2227589) with the risk of thrombosis. Hence, in the present study, we conducted a case-control study to further evaluate the association between the variant rs2227589 with antithrombin deficiency in pulmonary embolism (PTE). A pooled systematic analysis was also conducted to evaluate the risk of rs2227589 in venous thromboembolism (VTE) among multiple populations. This case-control study involved 101 patients and 199 healthy controls. The allele frequency of variant rs2227589 was analyzed by Sequenom assay. Antithrombin anticoagulant activity was detected using an automatic coagulation analyzer. In addition, a pooled systematic analysis on 10 cohorts consisting of 5,518 patients with VTE and 8,935 controls was performed. In total, 27 (26.7%) PTE subjects were diagnosed as having antithrombin deficiency. Our results showed that antithrombin plasma activity was slightly lower in T allele carriers than that in C allele carriers. However, there was no significant correlation between rs2227589 genotype and antithrombin anticoagulant activity. The recessive model showed that rs2227589 was significantly associated (p = 0.026) with an increased risk {odds ratio [OR]: 2.31, 95% confidence interval [CI] (1.09-4.89)} of Chinese PTE. The pooled systematic analysis of all case-control study and meta-analysis showed that rs2227589 polymorphism was associated with an increased risk of VTE in the additive model [OR: 1.09, 95% CI (1.01-1.18), P = 0.029] and dominant model [OR: 1.10, 95% CI (1.01-1.20), P = 0.034]. Our study demonstrated that variant rs2227589 is associated with an increased risk of PTE in a Chinese population but no correlation with antithrombin anticoagulant activity. However, pooled systematic analysis of multiple populations showed a significant association between rs2227589 and the risk of VTE in the additive and dominant genetic model.
该基因中的遗传变异已被证明与抗凝血酶缺乏有关,这随后导致了静脉血栓形成的易感性。然而,其他几项研究在该基因多态性(rs2227589)与血栓形成风险的关联方面得出了相互矛盾的结果。因此,在本研究中,我们进行了一项病例对照研究,以进一步评估rs2227589变异与肺栓塞(PTE)中抗凝血酶缺乏之间的关联。还进行了一项汇总系统分析,以评估多人群中rs2227589在静脉血栓栓塞(VTE)中的风险。这项病例对照研究涉及101例患者和199名健康对照。通过Sequenom检测法分析rs2227589变异的等位基因频率。使用自动凝血分析仪检测抗凝血酶抗凝活性。此外,对由5518例VTE患者和8935名对照组成的10个队列进行了汇总系统分析。总共27例(26.7%)PTE受试者被诊断为患有抗凝血酶缺乏。我们的结果表明,T等位基因携带者的抗凝血酶血浆活性略低于C等位基因携带者。然而,rs2227589基因型与抗凝血酶抗凝活性之间没有显著相关性。隐性模型显示,rs2227589与中国PTE风险增加显著相关(p = 0.026){优势比[OR]:2.31,95%置信区间[CI](1.09 - 4.89)}。所有病例对照研究和荟萃分析的汇总系统分析表明,rs2227589多态性在加性模型[OR:1.09,95% CI(1.01 - 1.18),P = 0.029]和显性模型[OR:1.10,95% CI(1.01 - 1.20),P = 0.034]中与VTE风险增加相关。我们的研究表明,rs2227589变异与中国人群中PTE风险增加相关,但与抗凝血酶抗凝活性无关。然而,多人群的汇总系统分析表明,rs2227589与加性和显性遗传模型中VTE风险之间存在显著关联。